Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.65Last Year’s EPS
1.62Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 7.59%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
Collegium Pharmaceutical demonstrated strong revenue growth and strategic progress, particularly with Jornay PM and in expanding their sales force. However, increased operating expenses and pressures on net income and the pain portfolio present some challenges. The overall sentiment of the call is positive due to the strong growth metrics and strategic initiatives outweighing the challenges.Company Guidance
During the Collegium Pharmaceutical First Quarter 2025 Earnings Conference Call, the company provided significant financial guidance and updates on its strategic priorities. Collegium reported a 23% year-over-year increase in revenue for the first quarter, with total net product revenues reaching $177.8 million. Key contributors to this growth included a $28.5 million net revenue from Jornay PM, reflecting a 24% year-over-year prescription growth, and a 3% increase in revenues from the pain portfolio, which brought in $149.2 million. The company reaffirmed its 2025 financial guidance, projecting net product revenues between $735 million to $750 million and adjusted EBITDA of $435 million to $450 million. Additionally, Collegium announced a $25 million accelerated share repurchase program and highlighted its focus on strategic capital deployment, which includes expanding the sales force for Jornay PM and paying down debt efficiently.Strong Revenue Growth
Collegium Pharmaceutical reported 23% year-over-year revenue growth in the first quarter of 2025, driven by significant contributions from Jornay PM and their pain portfolio.
Jornay PM Performance
Jornay PM prescriptions grew 24% year-over-year, generating $28.5 million in net revenue in its second full quarter of ownership. The company expects Jornay PM to generate at least $135 million in annual revenue, representing 34% growth from 2024.
Expansion of Sales Force
Collegium expanded their ADHD sales force by adding 55 new representatives, bringing the total to 180, to further accelerate prescription growth for Jornay PM.
Recognition as a Top Workplace
Collegium was recognized in USA TODAY’s Top Workplaces list and the Boston Business Journal’s Best Places to Work for the second year in a row.
Board and Leadership Updates
Collegium announced updates to their Board of Directors and executive leadership team, including the appointment of new leaders and the retirement of long-serving board members.
$25 Million Accelerated Share Repurchase Program
The Board authorized a $25 million accelerated share repurchase program, reinforcing their commitment to return value to shareholders.
Strong Financial Position
Collegium generated $55.4 million in cash from operations, increased their cash position to nearly $200 million, and paid down $16.1 million of debt.
---
COLL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
COLL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $27.27 | $28.89 | +5.94% |
Feb 27, 2025 | $28.42 | $29.05 | +2.22% |
Nov 07, 2024 | $34.71 | $32.16 | -7.35% |
Aug 08, 2024 | $35.32 | $35.50 | +0.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Collegium Pharmaceutical (COLL) report earnings?
Collegium Pharmaceutical (COLL) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Collegium Pharmaceutical (COLL) earnings time?
Collegium Pharmaceutical (COLL) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is COLL EPS forecast?
COLL EPS forecast for the fiscal quarter 2025 (Q2) is 1.65.
---